Latest Us Expansion News

dorsaVi reports strong US commercial growth with over 100 new physical therapy sites and a 50% rise in cash receipts, alongside a strategic leadership change and breakthrough neuromorphic technology acquisition.

Metallium Limited has kicked off commissioning at its Texas Technology Campus, sealed a multi-year feedstock deal with Glencore, and bolstered its balance sheet with a A$75 million capital raise, setting the stage for commercialisation in 2026.

Tinybeans Group’s acquisition of US-based Qeepsake fuels a sharp revenue jump and improved profitability in Q2 FY26, signalling early success in its growth strategy.

Control Bionics has partnered with Tobii Dynavox to pilot its NeuroNode technology across five US states, aiming to enhance communication access for users of augmentative devices.

Adveritas Limited has reported a record $14.25 million annualised recurring revenue for the December 2025 quarter, driven by strong US market growth and AI-enhanced product development. The company’s strategic focus on media agency partnerships and new product lines signals robust momentum ahead.

Orthocell Limited has reported a record $3.2 million revenue for the December 2025 quarter, marking its seventh consecutive quarter of growth, fuelled by expanding sales of its nerve repair product Remplir in the US and other international markets.

Terra Critical Minerals has completed the acquisition of the True American Tungsten Project in Nevada, positioning itself to capitalise on soaring tungsten prices and supply constraints. The company plans extensive exploration in 2026 to validate and expand this historically high-grade asset.

Vitasora Health has completed an A$11 million capital raise, including a cornerstone investment, bolstering its balance sheet to support ambitious growth in the US healthcare market. The company targets cash flow breakeven by the end of FY2026 amid expanding patient programs and new partnerships.

4DMedical Limited has raised $150 million through a well-supported institutional placement to accelerate the commercialisation of its innovative lung imaging product CT – VQ™ in the US market. The capital raise comes with minimal dilution and increased insider confidence.

ECS Botanics reports a $218k positive operating cash flow in Q2 FY26, driven by strong B2C growth and new product launches. The company also secured $1.95 million in funding to fuel European expansion and product development.

Cyclopharm secures a landmark deal with Lucile Packard Children’s Hospital Stanford to introduce Technegas, marking the first dedicated children’s hospital in the US to adopt this advanced lung imaging technology.

Energy Transition Minerals (ETM) has appointed Ballard Partners as strategic advisors in the US, reinforcing its plan to list on the Nasdaq Stock Exchange and deepen its engagement with American stakeholders.